| Literature DB >> 22809456 |
Ramakanth Sarabu1, Fred T Bizzarro, Wendy L Corbett, Mark T Dvorozniak, Wanping Geng, Joseph F Grippo, Nancy-Ellen Haynes, Stanley Hutchings, Lisa Garofalo, Kevin R Guertin, Darryl W Hilliard, Marek Kabat, Robert F Kester, Wang Ka, Zhenmin Liang, Paige E Mahaney, Linda Marcus, Franz M Matschinsky, David Moore, Jagdish Racha, Roumen Radinov, Yi Ren, Lida Qi, Michael Pignatello, Cheryl L Spence, Thomas Steele, John Tengi, Joseph Grimsby.
Abstract
Glucokinase (GK) activation as a potential strategy to treat type 2 diabetes (T2D) is well recognized. Compound 1, a glucokinase activator (GKA) lead that we have previously disclosed, caused reversible hepatic lipidosis in repeat-dose toxicology studies. We hypothesized that the hepatic lipidosis was due to the structure-based toxicity and later established that it was due to the formation of a thiourea metabolite, 2. Subsequent SAR studies of 1 led to the identification of a pyrazine-based lead analogue 3, lacking the thiazole moiety. In vivo metabolite identification studies, followed by the independent synthesis and profiling of the cyclopentyl keto- and hydroxyl- metabolites of 3, led to the selection of piragliatin, 4, as the clinical lead. Piragliatin was found to lower pre- and postprandial glucose levels, improve the insulin secretory profile, increase β-cell sensitivity to glucose, and decrease hepatic glucose output in patients with T2D.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22809456 DOI： 10.1021/jm3008689
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446